HIV remission in Oslo patient & Iran war reshapes nuclear plans - News (Apr 18, 2026)

First up, a striking medical update: researchers say a 63-year-old Norwegian man—now known as the “Oslo patient”—is in long-term HIV remission five years after a stem cell transplant that was originally done to treat a serious blood disorder. What makes this case stand out is the donor: his brother. And the donor carried two copies of a rare genetic change, called CCR5Δ32, that blocks one of the main ways HIV gets into immune cells. After extensive testing, scientists report they can’t find the usual hidden reservoirs of the virus in blood, gut, or bone marrow. They’re careful with language, but the takeaway is clear: this is another rare, credible example of a functional cure. It’s not a treatment path most people could or should pursue—transplants are risky and used only when there’s another life-threatening condition. Still, each case helps researchers narrow down what a safer, scalable remission strategy might need: the right immune environment, the right genetics, and the right timing.

Now to the energy story that’s reshaping policy from Asia to Africa. Disruptions tied to the Iran war—especially snarled fuel shipments and the ripple effects of instability around key shipping lanes—are pushing governments to hedge against future oil and gas shocks. One major hedge that’s coming back into favor is nuclear power. Countries that already have reactors are trying to squeeze more electricity out of what’s running. South Korea is ramping generation, while Japan and Taiwan are reconsidering capacity that had been reduced or shut down after Fukushima-era pullbacks. Meanwhile, newer nuclear entrants are moving faster: Bangladesh is trying to bring Russian-built reactors online, Vietnam has signed a deal for Russian-designed plants, and the Philippines is once again revisiting a long-dormant facility. In Africa, interest is broad and growing, with more than 20 countries pursuing nuclear plans in some form. Small modular reactors are getting extra attention because they’re pitched as easier to scale for weaker grids and fast-rising demand. South Africa, the continent’s most established nuclear operator, is also signaling it wants a much bigger nuclear slice of its power mix. The bigger picture is geopolitical: as nuclear plans spread, so does influence. Suppliers including Russia, the U.S., China, France, and South Korea are competing for contracts and long-term partnerships that can last decades. Supporters argue nuclear can stabilize power systems when fuel markets are chaotic. Critics counter with familiar—and serious—concerns: safety, long-lived radioactive waste, proliferation risks, and the vulnerability of nuclear sites during conflict, while arguing renewables can deliver energy security faster and at lower risk.

That same energy shock is also accelerating a different shift: countries and consumers are buying more electrified alternatives, and China is benefiting quickly. Customs data for March showed China’s clean-tech exports jumping year over year—strong gains in lithium-ion batteries, electric vehicles, and solar cells, all accelerating compared with February. Analysts see it as an early signal of what happens when fuel prices spike and supply feels uncertain: demand rises for technologies that reduce dependence on imported oil and gas. EV and hybrid exports hit a record pace, and dealers in several Asian capitals are describing a practical consumer motivation: people don’t want to be trapped by gasoline prices. Add in the fact that some exporters rushed shipments ahead of expected policy changes to tax rebates, and you get a surge that could help China expand its overseas market share even further—especially given its already dominant position across solar, batteries, and EV supply chains.

Shifting to artificial intelligence and health research, OpenAI has launched a new model series called GPT-Rosalind, built specifically for life sciences. The point here isn’t that it’s “an AI that knows biology.” The claim is more ambitious: that it can help researchers navigate the messy, multi-step work of modern biomedical science—reading and synthesizing literature, connecting dots across genes and pathways, planning experiments, and analyzing data—so teams can test better ideas faster. OpenAI says it’s already being tried with major biotech and research partners, including Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific. If it performs as advertised, it could shorten the early stages of drug discovery and raise the competitive stakes in AI-driven medicine, where speed to a strong hypothesis can mean everything.

Another AI story today is less about laboratories and more about your personal data. Google says it’s rolling out a personalized image-generation feature that can connect Gemini to your private Google Photos library—if you opt in. In plain terms: instead of uploading pictures into a chatbot, you’d let the system reference your existing photo collection to generate new images featuring you or your family in different styles or scenes. Google says it doesn’t directly train its models on users’ Google Photos, but it may use limited information like prompts and responses, and it can reference labeled people in Photos. This is part of a broader trend in consumer AI: personalization is getting deeper, and that means the privacy questions get sharper. The convenience is obvious. The tradeoff is deciding how comfortable you are with a chatbot having a tighter link to your most personal archive.

And staying with AI, a new Stanford HAI report argues China has nearly closed the performance gap with the U.S. in top chatbot quality, based on a narrowing spread in “Arena” benchmark scores from 2023 through early 2026. The U.S. still turns out more top-tier models overall, but the report says China is leading on several scale indicators—things like citations, patents, and industrial robot installations. It also points to heavy investment momentum after a 2025 “DeepSeek moment,” plus a strong pipeline of AI-linked public listings and, importantly, abundant power generation that can support rapid data-center expansion. On the U.S. side, the warning is blunt: even with capital and talent, an aging electricity grid could become a real bottleneck. The report also notes the U.S. “brain gain” in AI appears to be weakening compared with past years—still positive, but less dominant than it once was. The implication is that leadership won’t be protected by export controls alone; it’ll depend on infrastructure, talent flows, and sustained innovation.

Now to public health in the U.S., where the measles story is turning into a test of credibility and policy. The Associated Press fact-checked Health and Human Services Secretary Robert F. Kennedy Jr.’s claim that the U.S. is limiting measles outbreaks better than any country in the world. AP notes measles is surging globally, and some countries do have larger outbreaks than the U.S. right now. But the key point is that America’s situation is not trending in the right direction. Falling vaccination rates are a major driver, and the U.S. is now experiencing its biggest measles surge since 1991, with 2026 cases already on track to beat last year’s record totals. Childhood vaccination coverage has slipped notably over the past few years, and experts warn that if coverage doesn’t rebound, the U.S. could risk losing its measles elimination status—a designation that depends on maintaining very high immunity levels. The practical takeaway: measles isn’t just “back.” It’s exploiting gaps created by declining vaccination, and public messaging matters because small changes in coverage can have outsized effects.

Two more quick health and science updates. First, a neuroscience paper in Neuron reports new evidence mapping the brain circuits behind placebo pain relief. Researchers found a pathway linking higher brain regions to pain-control centers in the brainstem and down toward the spinal cord, and they detected natural opioid signaling during placebo-driven relief. They also showed that blocking that opioid signaling disrupted both placebo relief and morphine relief. Why it’s interesting: it adds biological weight to the idea that expectation and learning can measurably change pain—potentially opening doors to opioid-sparing strategies that complement medical care, especially around surgery or chronic pain. Second, Eli Lilly says late-stage trial results for its oral obesity drug, Foundayo, show more than weight and blood-sugar improvements. In a study of higher-risk patients with type 2 diabetes and obesity, the company reports a reduction in major cardiovascular events compared with a common insulin treatment, along with lower overall mortality. Lilly also says it saw no liver safety red flags in the analysis it highlighted. If regulators agree with the broader safety and benefits profile, the news adds momentum to the push for convenient pill-based metabolic therapies—and it raises the competitive pressure in a market currently defined by powerful injectables and a race to prove heart-protection benefits, not just weight loss.